Stratified Medicine – Diagnostics for Adverse or Non-Response

Stratified Medicine – Diagnostics for Adverse or Non-Response

14 Mar 2012

The government is inviting UK companies to apply for funding to develop tests that will identify patients at risk of either suffering an adverse response or not responding to specific therapies.

The Technology Strategy Board in partnership with Department of Health ( will invest up to £7.5 million through the award of development contracts.  Selection will be made primarily on the potential value of the proposed products to the health service.

The competition aims to bring together the different players necessary to evaluate the best ways to develop and implement such diagnostic tests, establish the clinical value chain and determine the potential for commercialisation and uptake of the tests.  The competition also aims to establish if Stratified Medicine approaches can be used to improve the current clinical care pathway in the UK to address the risks of side effects or adverse reactions and/or identifying non-responders to treatments.

Proposals for funding should be industrially-focussed and business-driven, and must clearly present the economic benefits to be gained through exploitation of the product.  Support will be provided to projects seeking to develop innovative products such as diagnostic tests and/or analytical algorithms capable of predicting either an adverse responder to a specific therapy, those who will not respond to a therapy (non-responder) or can provide early indication that a patient is not responding to treatment.  The projects must address a treatment (whether it involves a medicine, medical device or procedure) which is currently licensed for use in the UK.

The competition will be run through the SBRI programme, which provides for development contracts to be 100% funded, and it will be run in two phases.  Applicants successful in the first phase will be funded to produce a development plan including a detailed assessment of the economic value of the product.  The products with the best value combined with technical feasibility will be selected in phase 2 for development.

The competition opens on 26 March 2012 and the deadline for registration is 6 June 2012.  Applications must then be submitted by 13 June 2012.  A briefing day for potential applicants will be held on 4 April. 

View further information about the competition here

View the media alert including notes to editors here

This video requires flash version 7 or higher to play.

Last updated on Wednesday 14 March 2012 at 11:30

More like this

See more content in the <Medicines and healthcare> area

Copyright © 2013